RxDoctor Payments Data

Kelli Buckner, DO

Family Medicine · Cleveland, OHNPI 1417269622

Payments from drug & device makers

$1,290in general payments, 2019–2025

Across 38 payments — averaging $33.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$245
  • AbbVie$217
  • Novo Nordisk$196
  • GSK$152
  • Lilly USA, LLC$144
  • Smith+Nephew$116
  • plus $221 from 7 others

What the payments were for

  • Food & beverage$1,290100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,290 in reported general payments places this provider in the 65th percentile of 3,983 family medicine providers in Ohio.

See all family medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$4,387
Medicare patients
29
Services billed
64

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin71$108,407
MounjaroTirzepatide31$37,308
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr59$31,324
EliquisApixaban31$31,164
Trelegy ElliptaFluticasone/Umeclidin/Vilanter39$26,241
OzempicSemaglutide24$25,024
TrulicityDulaglutide24$23,201
FarxigaDapagliflozin Propanediol15$13,263
VascepaIcosapent Ethyl15$10,057
SymbicortBudesonide/Formoterol Fumarate37$9,024
Aimovig AutoinjectorErenumab-Aooe12$8,871
Spiriva RespimatTiotropium Bromide16$8,549
Lidocaine21$2,806
Albuterol Sulfate HfaAlbuterol Sulfate115$2,481
LantusInsulin Glargine,hum.Rec.Anlog20$2,422

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Spiriva Respimat$245$116,95687 claims
Lilly USA, LLCMounjaro, Trulicity$144$60,50955 claims
GSKAnoro Ellipta, Trelegy Ellipta$152$57,56598 claims
Novo NordiskOzempic$196$25,02424 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,983 family medicine providers in Ohio.

Other family medicine in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →